menu
    • menu
    [{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"||Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Merger","leadProduct":"Beta-tricalcium Phosphate","moa":"||Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp"},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Phosphate","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Carmell Therapeutics

    Menu

    Carmell Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Axolotl Biologix

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Axolotl Biologix

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axolotl Graft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Carmell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medici...

                            Details : Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for sk...

                            Product Name : Axolotl Graft

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 09, 2023

                            Lead Product(s) : Axolotl Graft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Carmell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Axolotl Biologix

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Axolotl Biologix

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axolotl Graft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Carmell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

                            Details : Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for sk...

                            Product Name : Axolotl Graft

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 08, 2023

                            Lead Product(s) : Axolotl Graft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Carmell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Axolotl Biologix

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Axolotl Biologix

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axolotl Graft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Carmell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company

                            Details : Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for sk...

                            Product Name : Axolotl Graft

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 27, 2023

                            Lead Product(s) : Axolotl Graft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Carmell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Axolotl Biologix

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Axolotl Biologix

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axolotl Graft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Carmell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organization...

                            Details : Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for sk...

                            Product Name : Axolotl Graft

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 09, 2023

                            Lead Product(s) : Axolotl Graft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Carmell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Carmell Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Carmell Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Calcium Phosphate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Sponsor : Alpha Healthcare Acquisition Corp

                            Deal Size : $154.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnolo...

                            Details : Carmell Therapeutics is in early preclinical testing of BHA product as an orthobiolgoic to determine the capability of BHA to act as an enhancer to existing bone graft substitutes as well as a stand-alone new alternative to bone graft substitute products...

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            April 01, 2023

                            Lead Product(s) : Undisclosed,Calcium Phosphate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Sponsor : Alpha Healthcare Acquisition Corp

                            Deal Size : $154.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Carmell Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Carmell Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcium Phosphate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carmell Therapeutics Receives IND Clearance for CT-101, Bone Healing Accelerant

                            Details : Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 01, 2020

                            Lead Product(s) : Calcium Phosphate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Carmell Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed

                            Carmell Therapeutics

                            U.S.A arrow
                            STLE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcium Phosphate,Undisclosed

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant

                            Details : The Fast Track status offers the company benefits in improving and accelerating the company's trial on Bone Healing Accelerant in open tibia fractures to the target of a Biologic License Application.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 27, 2020

                            Lead Product(s) : Calcium Phosphate,Undisclosed

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth